A target-agnostic engine for first-in-class drugs
Grove Biopharma’s integrated discovery platform combines AI-enabled molecular design, precision polymer chemistry and experimental biology to create proprietary Bionic Biologics™ against challenging targets.
Our platform is designed to address intracellular protein-protein interaction targets that have remained beyond the reach of conventional biologics and small molecules. With our proprietary technology, every protein and protein complex is now in play.
Our platform transforms peptides into Bionic Biologics with predictable pharmacology
Bionic Biologics begin with target-binding peptides identified through advanced AI/ML and physics-based computational design, structural biology, antibody CDRs, or phage display technology.
We create modular bionic building blocks with these peptide inputs, then assemble them into protein-scale molecules through a novel precision polymerization process.
This bionic architecture confers unique properties that amplify the function of the peptide inputs. While an individual peptide has a short half-life and cannot penetrate cells, Bionic Biologics are highly stable, potent, and cell permeant, with long half-life. Peptides are transformed into therapeutics that can access intracellular targets.
Bionic Biologics are a novel modality optimal for drug applications
Inherently cell permeable
Dynamic amphiphilicity allows Bionic Biologics to do what other biologics cannot: get into cells to engage PPI targets.
Customizable
Bionic Biologics can be designed as monofunctional or bispecific molecules, to disrupt or degrade protein-protein interactions.
Potent, protein-scale, avidity enhanced intracellular PPI disruptors
Hijacking or mimicking adapter domains or protein degradation machinery
AI enabled
AI-guided molecular design, combined with modular chemistry and well-defined platform design rules make it simple to create protein-scale molecules that can reach the most complex and formidable targets, such as transcription factors and Ser/Thr phosphatase complexes.
FAQs
Selected Publications
Callman C, et al. "Poly(peptide): Synthesis, Structure, and Function of Peptide-Polymer Amphiphiles and Protein-like Polymers” Acc. Chem. Res. 2020; 53 (2): 400–413. DOI: 10.1021/acs.accounts.9b00518.
Sun H, et al. “Origin of Proteolytic Stability of Peptide-Brush Polymers as Globular Proteomimetics” ACS Cent. Sci. 2021; 7: 2063−2072. DOI:10.1021/acscentsci.1c01149
Oktawiec J, et al. “Conformational modulation and polymerization induced folding of proteomimetic peptide brush polymers” Chem. Sci. 2024; 15: 13899. DOI: 10.1039/D4SC03420A
Choi W, et al. “Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model” Sci. Adv. 2023; 9 (41). DOI: 10.1126/sciadv.adi8534
